TY - JOUR
T1 - A randomized, controlled trial of weekly administration of lymphoblastoid interferon in patients with chronic hepatitis C
AU - Kagawa, Tatehiro
AU - Morizane, Toshio
AU - Saito, Hidetsugu
AU - Miyaguchi, Shingo
AU - Tsunematsu, Satoshi
AU - Tada, Shinichirou
AU - Guevara, Ferdinand M.
AU - Kumagai, Naoki
AU - Tsuchimoto, Kanji
AU - Watanabe, Tetsu
AU - Tsuchiya, Masaharu
N1 - Funding Information:
Part of this work was supported by a Grant-in-Aid for Science Research from the Ministry of Education, Science and Culture, and the Ministry of Health and Welfare of Japan. We would like to express our heartfui gratitude to Mr. Martin Peters for editing the manuscript.
PY - 1993
Y1 - 1993
N2 - To evaluate the efficacy of a treatment of weekly interferon administration in patients with chronic hepatitis C, 36 patients were randomly assigned to two groups. In one group lymphoblastoid interferon was given at a dose of 6 million units, intramuscularly, once per week for 24 weeks, and no treatment was given to the other. Serum alanine aminotransferase levels in the treated group were significantly lower during therapy than in the control group, although there was no significant difference between these two groups before therapy. The normalization of serum alanine aminotransferase levels at the end of therapy was observed in 50% of the treated group, and in 11.1% of the control group. This difference was statistically significant (p < 0.03). Response to interferon was better in patients with chronic persistent hepatitis or with chronic active hepatitis than in patients with chronic active hepatitis with cirrhosis. Relapse after the end of therapy was observed in 83.3% of the responders. These results indicate that the weekly administration of 6 million units of lymphoblastoid interferon is effective in decreasing serum alanine aminotransferase levels in patients with type C chronic persistent hepatitis or chronic active hepatitis.
AB - To evaluate the efficacy of a treatment of weekly interferon administration in patients with chronic hepatitis C, 36 patients were randomly assigned to two groups. In one group lymphoblastoid interferon was given at a dose of 6 million units, intramuscularly, once per week for 24 weeks, and no treatment was given to the other. Serum alanine aminotransferase levels in the treated group were significantly lower during therapy than in the control group, although there was no significant difference between these two groups before therapy. The normalization of serum alanine aminotransferase levels at the end of therapy was observed in 50% of the treated group, and in 11.1% of the control group. This difference was statistically significant (p < 0.03). Response to interferon was better in patients with chronic persistent hepatitis or with chronic active hepatitis than in patients with chronic active hepatitis with cirrhosis. Relapse after the end of therapy was observed in 83.3% of the responders. These results indicate that the weekly administration of 6 million units of lymphoblastoid interferon is effective in decreasing serum alanine aminotransferase levels in patients with type C chronic persistent hepatitis or chronic active hepatitis.
KW - Hepatitis C virus
KW - Human lymphoblastoid interferon
KW - Treatment
KW - Weekly injection
UR - http://www.scopus.com/inward/record.url?scp=0027534328&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027534328&partnerID=8YFLogxK
U2 - 10.1016/S0168-8278(05)80527-6
DO - 10.1016/S0168-8278(05)80527-6
M3 - Article
C2 - 8445225
AN - SCOPUS:0027534328
SN - 0168-8278
VL - 17
SP - 91
EP - 96
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 1
ER -
